BVXV - Novavax: Anticipation Builds With Major Catalysts Just Around The Corner
The Wait On The ResVax Preliminary Data Is Nearly Over
A couple of months ago I wrote an article on Novavax (NVAX) detailing the upcoming catalysts set to hit in early 2019 stating the stock would remain in the $1.50-$2.50 price range as anticipation builds on the release of 2 main preliminary trial data updates. Since then the stock has traded as high as $2.48 and as low as $1.73. It now rests right around the middle of this range and this will likely be the last time it trades around this area